Vaxart’s influenza vaccines currently in development promise numerous advantages over existing vaccines and technologies.
A tablet instead of a shot is preferable to most people and eliminates needle aversion as an obstacle to vaccination. Patients can more easily take the Vaxart vaccine themselves, as no injection devices are necessary.
Patients can easily take the Vaxart vaccine themselves, as no injection devices are necessary. We believe the convenience of the tablet will make it easier to reach those who could benefit from immunization, greatly increasing vaccination rates.
We believe Vaxart’s vaccine tablets are resilient. They have shown room temperature stability for more than one year. With no need for a cold chain in distribution, Vaxart vaccines could be shipped by standard mail, greatly improving access and availability while reducing costs. The vaccines can also be stockpiled and stored longer-term under refrigeration at any point in distribution.
Vaxart’s goal is to use efficient, standardized, high-yield manufacturing methods, with essentially the same process for every Vaxart vaccine, saving time and resources.
Using modular creation with standard recombinant techniques, Vaxart intends to create new vaccines very quickly to protect against emerging pathogens such as avian influenza or even biodefense threats.
Vaxart vaccines do not contain whole killed or attenuated (weakened) influenza virus. No eggs are used in the production process.